AGÕæÈ˹ٷ½

STOCK TITAN

Phreesia Announces Second Quarter Fiscal 2026 Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)-- Phreesia, Inc. (NYSE: PHR) (“Phreesia� or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2025.

“I am proud to share that Phreesia has had many noteworthy developments over the past quarter. In addition to delivering another solid set of financial results, including achieving our first-ever net income positive quarter, we have expanded our reach and capabilities, positioning us well for the future. I am also excited to share that we entered into a definitive agreement to acquire AccessOne, a market leader in providing financing solutions for healthcare receivables. Please refer to the AccessOne press release published earlier today for additional details,� said CEO and Co-Founder Chaim Indig.

Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal 2026 Stakeholder Letter.

Fiscal Second Quarter Ended July 31, 2025 Highlights

  • Total revenue was $117.3 million in the quarter, up 15% year-over-year.
  • Average number of healthcare services clients ("AHSCs") was 4,467 in the quarter, up 7% year-over-year.
  • Total revenue per AHSC was $26,249 in the quarter, up 7% year-over-year. See "Key Metrics" below for additional information.
  • Net income was $0.7 million in the quarter, as compared to net loss of $18.0 million in the same period in the prior year.
  • Adjusted EBITDA1 was $22.1 million in the quarter, as compared to $6.5 million in the same period in the prior year.
  • Net cash provided by operating activities was $14.8 million in the quarter, as compared to $11.1 million in the same period in the prior year.
  • Free cash flow2 was $9.6 million in the quarter, as compared to $3.7 million in the same period in the prior year.
  • Cash and cash equivalents as of July 31, 2025 was $98.3 million, an increase of $14.1 million from January 31, 2025 and up $7.4 million from April 30, 2025.

AccessOne Acquisition

Today, Phreesia announced that it has entered into a definitive agreement to acquire AccessOne Parent Holdings, Inc. (together with its subsidiaries, “AccessOne�), which will expand our suite of payment solutions. The transaction is expected to close during the third quarter or early fourth quarter of Phreesia’s 2026 fiscal year, subject to customary closing conditions and regulatory approvals.

AccessOne is a market leader in providing financing solutions for healthcare receivables, working with some of the largest health systems in the U.S. AccessOne takes minimal credit risk and offers healthcare providers a scalable, compliant and operationally efficient tool that improves collections without undermining patient trust. We believe the addition of AccessOne’s platform is a natural progression that will integrate well with our existing products.

“We have followed AccessOne’s progress over many years and admired its approach to addressing a critical gap in care that is consistent with our mission of making care easier every day,� said Chaim Indig, Phreesia’s CEO and Co-Founder.

For more information, please see our Current Report on Form 8-K filed with the SEC on September 4, 2025.

Fiscal 2026 Outlook

We are maintaining our revenue outlook for fiscal 2026. We expect revenue to be in the range of $472 million to $482 million. The revenue range provided for fiscal 2026 assumes no additional revenue from the AccessOne Acquisition or other potential future acquisitions completed between now and January 31, 2026.

We are updating our Adjusted EBITDA outlook for fiscal 2026 to a range of $87 million to $92 million from a previous range of $85 million to $90 million. The Adjusted EBITDA range provided for fiscal 2026 assumes continued improvements in operating leverage across the Company through a focus on efficiency and does not take into account the AccessOne Acquisition.

We are maintaining our expectation for AHSCs to reach approximately 4,500 in fiscal 2026. Additionally, we expect total revenue per AHSC in fiscal 2026 to increase from fiscal 2025.

We expect to update our fiscal 2026 financial outlook following the close of the AccessOne Acquisition.

We believe our $98.3 million in cash and cash equivalents as of July 31, 2025, along with cash generated in our normal operations, gives us sufficient flexibility to reach our fiscal 2026 outlook. Additionally, our available borrowing capacity under our credit facility with Capital One provides us with an additional source of capital to pursue future growth opportunities not incorporated into our fiscal 2026 outlook. As of July 31, 2025 we had no borrowings outstanding under our credit facility. In addition, we intend to finance the AccessOne Acquisition through a combination of cash from our balance sheet and proceeds from a new, fully committed bridge loan.

Non-GAAP3 Financial Measures

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other (income) expense, net and income tax (benefit) expense, which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss). For further information regarding the non-GAAP financial measures included in this press release, including a reconciliation of GAAP to non-GAAP financial measures and an explanation of these measures, please see “Non-GAAP Financial Measures� below.

Available Information

We intend to use our Company website (including our Investor Relations website) as well as our Facebook, X, LinkedIn and Instagram accounts as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Forward Looking Statements

This press release includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or our future financial or operating performance and may contain projections of our future results of operations or of our financial information or state other forward-looking information. These statements include, but are not limited to, statements regarding: our future financial and operating performance, including our revenue, operating leverage, margins, Adjusted EBITDA and cash flows; the consummation of the AccessOne Acquisition and timing thereof; the expected results of the AccessOne Acquisition discussed herein, including an expansion of our total addressable market; our ability to finance our plans to achieve our fiscal 2026 outlook with our current cash balance and cash generated in the normal course of business; and our outlook for fiscal 2026, including our expectations regarding revenue, Adjusted EBITDA, AHSCs and total revenue per AHSC. In some cases, you can identify forward-looking statements by the following words: “may,� “will,� “could,� “would,� “should,� “expect,� “intend,� “plan,� “anticipate,� “believe,� “estimate,� “predict,� “project,� “potential,� “continue,� “ongoing,� or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks associated with: our ability to effectively manage our growth and meet our growth objectives; our focus on the long-term and our investments in growth; the ability of the parties to consummate the AccessOne Acquisition in a timely manner or at all; satisfaction of the conditions precedent to consummation of the AccessOne Acquisition, including the ability to secure required consents and regulatory approvals in a timely manner or at all; the ability to obtain funding for the AccessOne Acquisition; the ability to integrate operations or realize any operational or corporate synergies and other benefits from the AccessOne Acquisition; the competitive environment in which we operate; our ability to comply with the covenants in our credit agreement with Capital One; changes in market conditions and receptivity to our products and services; our ability to develop and release new products and services and successful enhancements, features and modifications to our existing products and services; our ability to maintain the security and availability of our platform; the impact of cyberattacks, security incidents or breaches impacting our business; changes in laws and regulations applicable to our business model; our ability to make accurate predictions about our industry and addressable market; our ability to attract, retain and cross-sell to healthcare services clients; our ability to continue to operate effectively with a primarily remote workforce and attract and retain key talent; our ability to realize the intended benefits of our acquisitions and partnerships; and difficulties in integrating our acquisitions and investments; artificial intelligence that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data, increasing our regulatory and compliance burden and increasing competition; and other general, market, political, economic and business conditions (including from the change in U.S. presidential administration, tariff and trade issues, and the warfare and/or political and economic instability in Ukraine, the Middle East or elsewhere). The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those listed or described in our filings with the Securities and Exchange Commission (“SEC�), including in our Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 that will be filed with the SEC following this press release. The forward-looking statements in this press release speak only as of the date on which the statements are made. We undertake no obligation to update, and expressly disclaim the obligation to update, any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

This press release includes certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, with the exception of our Adjusted EBITDA outlook for the reasons described above.

Conference Call Information

We will hold a conference call on Thursday, September 4, 2025 at 5:00 p.m. Eastern Time to review our fiscal 2026 second quarter financial results. To participate in our live conference call and webcast, please dial (800) 715-9871 (or (646) 307-1963 for international participants) using conference code number 7404611 or visit the “Events & Presentations� section of our Investor Relations website at ir.phreesia.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Phreesia

Phreesia is a trusted leader in patient activation, giving healthcare providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024�1 in 7 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes.

Phreesia, Inc.

Consolidated Balance Sheets

(in thousands, except share and per share data)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

July 31,

2025

Ìý

January 31,

2025

Ìý

Ìý

(Unaudited)

Ìý

Ìý

Assets

Ìý

Ìý

Ìý

Current:

Ìý

Ìý

Ìý

Cash and cash equivalents

$

98,266

Ìý

Ìý

$

84,220

Ìý

Settlement assets

Ìý

28,875

Ìý

Ìý

Ìý

29,176

Ìý

Accounts receivable, net of allowance for doubtful accounts of $2,654 and $1,468 as of July 31, 2025 and January 31, 2025, respectively

Ìý

76,842

Ìý

Ìý

Ìý

73,617

Ìý

Deferred contract acquisition costs

Ìý

431

Ìý

Ìý

Ìý

401

Ìý

Prepaid expenses and other current assets

Ìý

18,227

Ìý

Ìý

Ìý

15,871

Ìý

Total current assets

Ìý

222,641

Ìý

Ìý

Ìý

203,285

Ìý

Property and equipment, net of accumulated depreciation and amortization of $90,765 and $84,505 as of July 31, 2025 and January 31, 2025, respectively

Ìý

22,769

Ìý

Ìý

Ìý

23,651

Ìý

Capitalized internal-use software, net of accumulated amortization of $62,272 and $55,991 as of July 31, 2025 and January 31, 2025, respectively

Ìý

53,881

Ìý

Ìý

Ìý

52,763

Ìý

Operating lease right-of-use assets

Ìý

1,043

Ìý

Ìý

Ìý

1,477

Ìý

Deferred contract acquisition costs

Ìý

551

Ìý

Ìý

Ìý

583

Ìý

Intangible assets, net of accumulated amortization of $10,147 and $8,407 as of July 31, 2025 and January 31, 2025, respectively

Ìý

26,403

Ìý

Ìý

Ìý

28,143

Ìý

Goodwill

Ìý

75,845

Ìý

Ìý

Ìý

75,845

Ìý

Deferred tax asset

Ìý

1,640

Ìý

Ìý

Ìý

�

Ìý

Other assets

Ìý

3,856

Ìý

Ìý

Ìý

2,668

Ìý

Total Assets

$

408,629

Ìý

Ìý

$

388,415

Ìý

Liabilities and Stockholders� Equity

Ìý

Ìý

Ìý

Current:

Ìý

Ìý

Ìý

Settlement obligations

$

28,875

Ìý

Ìý

$

29,176

Ìý

Current portion of finance lease liabilities and other debt

Ìý

7,096

Ìý

Ìý

Ìý

8,043

Ìý

Current portion of operating lease liabilities

Ìý

941

Ìý

Ìý

Ìý

964

Ìý

Accounts payable

Ìý

6,527

Ìý

Ìý

Ìý

5,622

Ìý

Accrued expenses

Ìý

34,783

Ìý

Ìý

Ìý

37,460

Ìý

Deferred revenue

Ìý

26,913

Ìý

Ìý

Ìý

32,758

Ìý

Total current liabilities

Ìý

105,135

Ìý

Ìý

Ìý

114,023

Ìý

Long-term finance lease liabilities and other debt

Ìý

4,576

Ìý

Ìý

Ìý

8,150

Ìý

Operating lease liabilities, non-current

Ìý

179

Ìý

Ìý

Ìý

646

Ìý

Long-term deferred revenue

Ìý

81

Ìý

Ìý

Ìý

119

Ìý

Long-term deferred tax liabilities

Ìý

626

Ìý

Ìý

Ìý

484

Ìý

Other long-term liabilities

Ìý

45

Ìý

Ìý

Ìý

185

Ìý

Total Liabilities

Ìý

110,642

Ìý

Ìý

Ìý

123,607

Ìý

Commitments and contingencies

Ìý

Ìý

Ìý

Stockholders� Equity:

Ìý

Ìý

Ìý

Preferred stock, undesignated, $0.01 par value�20,000,000 shares authorized as of both July 31, 2025 and January 31, 2025; no shares issued or outstanding as of both July 31, 2025 and January 31, 2025

Ìý

�

Ìý

Ìý

Ìý

�

Ìý

Common stock, $0.01 par value�500,000,000 shares authorized as of both July 31, 2025 and January 31, 2025; 61,124,918 and 60,083,444 shares issued as of July 31, 2025 and January 31, 2025, respectively

Ìý

611

Ìý

Ìý

Ìý

601

Ìý

Additional paid-in capital

Ìý

1,147,540

Ìý

Ìý

Ìý

1,111,274

Ìý

Accumulated deficit

Ìý

(804,756

)

Ìý

Ìý

(801,496

)

Accumulated other comprehensive income (loss)

Ìý

112

Ìý

Ìý

Ìý

(51

)

Treasury stock, at cost, 1,355,169 shares as of both July 31, 2025 and January 31, 2025

Ìý

(45,520

)

Ìý

Ìý

(45,520

)

Total Stockholders� Equity

Ìý

297,987

Ìý

Ìý

Ìý

264,808

Ìý

Total Liabilities and Stockholders� Equity

$

408,629

Ìý

Ìý

$

388,415

Ìý

Phreesia, Inc.

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Revenue:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Subscription and related services

$

53,702

Ìý

Ìý

$

48,612

Ìý

Ìý

$

108,057

Ìý

Ìý

$

95,354

Ìý

Payment processing fees

Ìý

28,392

Ìý

Ìý

Ìý

25,300

Ìý

Ìý

Ìý

58,317

Ìý

Ìý

Ìý

52,360

Ìý

Network solutions

Ìý

35,161

Ìý

Ìý

Ìý

28,203

Ìý

Ìý

Ìý

66,817

Ìý

Ìý

Ìý

55,618

Ìý

Total revenues

Ìý

117,255

Ìý

Ìý

Ìý

102,115

Ìý

Ìý

Ìý

233,191

Ìý

Ìý

Ìý

203,332

Ìý

Expenses:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Cost of revenue (excluding depreciation and amortization)

Ìý

17,398

Ìý

Ìý

Ìý

16,143

Ìý

Ìý

Ìý

34,035

Ìý

Ìý

Ìý

31,866

Ìý

Payment processing expense

Ìý

20,243

Ìý

Ìý

Ìý

16,668

Ìý

Ìý

Ìý

41,671

Ìý

Ìý

Ìý

34,965

Ìý

Sales and marketing

Ìý

25,396

Ìý

Ìý

Ìý

30,184

Ìý

Ìý

Ìý

51,439

Ìý

Ìý

Ìý

62,195

Ìý

Research and development

Ìý

29,274

Ìý

Ìý

Ìý

29,542

Ìý

Ìý

Ìý

61,103

Ìý

Ìý

Ìý

58,423

Ìý

General and administrative

Ìý

19,042

Ìý

Ìý

Ìý

19,497

Ìý

Ìý

Ìý

35,450

Ìý

Ìý

Ìý

38,549

Ìý

Depreciation

Ìý

3,279

Ìý

Ìý

Ìý

3,921

Ìý

Ìý

Ìý

6,265

Ìý

Ìý

Ìý

7,445

Ìý

Amortization

Ìý

4,130

Ìý

Ìý

Ìý

3,382

Ìý

Ìý

Ìý

8,022

Ìý

Ìý

Ìý

6,531

Ìý

Total expenses

Ìý

118,762

Ìý

Ìý

Ìý

119,337

Ìý

Ìý

Ìý

237,985

Ìý

Ìý

Ìý

239,974

Ìý

Operating loss

Ìý

(1,507

)

Ìý

Ìý

(17,222

)

Ìý

Ìý

(4,794

)

Ìý

Ìý

(36,642

)

Other income (expense), net

Ìý

336

Ìý

Ìý

Ìý

(86

)

Ìý

Ìý

674

Ìý

Ìý

Ìý

(117

)

Interest income, net

Ìý

608

Ìý

Ìý

Ìý

46

Ìý

Ìý

Ìý

378

Ìý

Ìý

Ìý

285

Ìý

Total other income (expense), net

Ìý

944

Ìý

Ìý

Ìý

(40

)

Ìý

Ìý

1,052

Ìý

Ìý

Ìý

168

Ìý

Loss before income tax benefit (expense)

Ìý

(563

)

Ìý

Ìý

(17,262

)

Ìý

Ìý

(3,742

)

Ìý

Ìý

(36,474

)

Income tax benefit (expense)

Ìý

1,217

Ìý

Ìý

Ìý

(750

)

Ìý

Ìý

482

Ìý

Ìý

Ìý

(1,260

)

Net income (loss)

$

654

Ìý

Ìý

$

(18,012

)

Ìý

$

(3,260

)

Ìý

$

(37,734

)

Net income (loss) per share attributable to common stockholders:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

$

0.01

Ìý

Ìý

$

(0.31

)

Ìý

$

(0.06

)

Ìý

$

(0.66

)

Diluted

$

0.01

Ìý

Ìý

$

(0.31

)

Ìý

$

(0.06

)

Ìý

$

(0.66

)

Weighted-average common shares outstanding:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

59,591,545

Ìý

Ìý

Ìý

57,502,959

Ìý

Ìý

Ìý

59,261,722

Ìý

Ìý

Ìý

57,089,232

Ìý

Diluted

Ìý

61,685,811

Ìý

Ìý

Ìý

57,502,959

Ìý

Ìý

Ìý

59,261,722

Ìý

Ìý

Ìý

57,089,232

Ìý

Phreesia, Inc.

Unaudited Consolidated Statements of Comprehensive Income (Loss)

(in thousands)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net income (loss)

$

654

Ìý

Ìý

$

(18,012

)

Ìý

$

(3,260

)

Ìý

$

(37,734

)

Other comprehensive (loss) income:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net change in unrealized (losses) gains on cash flow hedges

Ìý

(199

)

Ìý

Ìý

�

Ìý

Ìý

Ìý

208

Ìý

Ìý

Ìý

�

Ìý

Change in foreign currency translation adjustments

Ìý

(73

)

Ìý

Ìý

(3

)

Ìý

Ìý

(45

)

Ìý

Ìý

(2

)

Other comprehensive (loss) income

Ìý

(272

)

Ìý

Ìý

(3

)

Ìý

Ìý

163

Ìý

Ìý

Ìý

(2

)

Comprehensive income (loss)

$

382

Ìý

Ìý

$

(18,015

)

Ìý

$

(3,097

)

Ìý

$

(37,736

)

Phreesia, Inc.

Unaudited Consolidated Statements of Cash Flows

(in thousands)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Operating activities:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net income (loss)

$

654

Ìý

Ìý

$

(18,012

)

Ìý

$

(3,260

)

Ìý

$

(37,734

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Depreciation and amortization

Ìý

7,409

Ìý

Ìý

Ìý

7,303

Ìý

Ìý

Ìý

14,287

Ìý

Ìý

Ìý

13,976

Ìý

Stock-based compensation expense

Ìý

16,230

Ìý

Ìý

Ìý

16,448

Ìý

Ìý

Ìý

33,455

Ìý

Ìý

Ìý

33,288

Ìý

Amortization of deferred financing costs and debt discount

Ìý

62

Ìý

Ìý

Ìý

51

Ìý

Ìý

Ìý

124

Ìý

Ìý

Ìý

112

Ìý

Cost of Phreesia hardware purchased by customers

Ìý

157

Ìý

Ìý

Ìý

334

Ìý

Ìý

Ìý

593

Ìý

Ìý

Ìý

677

Ìý

Deferred contract acquisition costs amortization

Ìý

242

Ìý

Ìý

Ìý

192

Ìý

Ìý

Ìý

352

Ìý

Ìý

Ìý

384

Ìý

Non-cash operating lease expense

Ìý

218

Ìý

Ìý

Ìý

188

Ìý

Ìý

Ìý

433

Ìý

Ìý

Ìý

361

Ìý

Deferred taxes

Ìý

(1,583

)

Ìý

Ìý

56

Ìý

Ìý

Ìý

(1,498

)

Ìý

Ìý

119

Ìý

Changes in operating assets and liabilities:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Accounts receivable

Ìý

(1,820

)

Ìý

Ìý

4,976

Ìý

Ìý

Ìý

(3,310

)

Ìý

Ìý

3,583

Ìý

Prepaid expenses and other assets

Ìý

(2,660

)

Ìý

Ìý

2,867

Ìý

Ìý

Ìý

(2,916

)

Ìý

Ìý

3,281

Ìý

Deferred contract acquisition costs

Ìý

(351

)

Ìý

Ìý

(213

)

Ìý

Ìý

(351

)

Ìý

Ìý

(213

)

Accounts payable

Ìý

2,068

Ìý

Ìý

Ìý

1,186

Ìý

Ìý

Ìý

329

Ìý

Ìý

Ìý

(1,750

)

Accrued expenses and other liabilities

Ìý

(1,289

)

Ìý

Ìý

(1,392

)

Ìý

Ìý

(2,180

)

Ìý

Ìý

(2,547

)

Lease liabilities

Ìý

(238

)

Ìý

Ìý

(201

)

Ìý

Ìý

(490

)

Ìý

Ìý

(420

)

Deferred revenue

Ìý

(4,264

)

Ìý

Ìý

(2,722

)

Ìý

Ìý

(5,883

)

Ìý

Ìý

(2,777

)

Net cash provided by operating activities

Ìý

14,835

Ìý

Ìý

Ìý

11,061

Ìý

Ìý

Ìý

29,685

Ìý

Ìý

Ìý

10,340

Ìý

Investing activities:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Capitalized internal-use software

Ìý

(3,435

)

Ìý

Ìý

(2,976

)

Ìý

Ìý

(7,323

)

Ìý

Ìý

(7,546

)

Purchases of property and equipment

Ìý

(1,767

)

Ìý

Ìý

(4,427

)

Ìý

Ìý

(5,271

)

Ìý

Ìý

(5,303

)

Net cash used in investing activities

Ìý

(5,202

)

Ìý

Ìý

(7,403

)

Ìý

Ìý

(12,594

)

Ìý

Ìý

(12,849

)

Financing activities:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Proceeds from issuance of common stock upon exercise of stock options

Ìý

114

Ìý

Ìý

Ìý

219

Ìý

Ìý

Ìý

242

Ìý

Ìý

Ìý

566

Ìý

Proceeds from employee stock purchase plan

Ìý

575

Ìý

Ìý

Ìý

690

Ìý

Ìý

Ìý

1,343

Ìý

Ìý

Ìý

1,603

Ìý

Finance lease payments

Ìý

(2,510

)

Ìý

Ìý

(1,995

)

Ìý

Ìý

(3,886

)

Ìý

Ìý

(3,275

)

Principal payments on financing agreements

Ìý

(328

)

Ìý

Ìý

(295

)

Ìý

Ìý

(648

)

Ìý

Ìý

(584

)

Debt issuance costs and loan facility fee payments

Ìý

�

Ìý

Ìý

Ìý

�

Ìý

Ìý

Ìý

(38

)

Ìý

Ìý

(152

)

Financing payments of acquisition-related liabilities

Ìý

�

Ìý

Ìý

Ìý

�

Ìý

Ìý

Ìý

�

Ìý

Ìý

Ìý

(1,364

)

Net cash used in financing activities

Ìý

(2,149

)

Ìý

Ìý

(1,381

)

Ìý

Ìý

(2,987

)

Ìý

Ìý

(3,206

)

Effect of exchange rate changes on cash and cash equivalents

Ìý

(89

)

Ìý

Ìý

(6

)

Ìý

Ìý

(58

)

Ìý

Ìý

(7

)

Net increase (decrease) in cash and cash equivalents

Ìý

7,395

Ìý

Ìý

Ìý

2,271

Ìý

Ìý

Ìý

14,046

Ìý

Ìý

Ìý

(5,722

)

Cash and cash equivalents � beginning of period

Ìý

90,871

Ìý

Ìý

Ìý

79,527

Ìý

Ìý

Ìý

84,220

Ìý

Ìý

Ìý

87,520

Ìý

Cash and cash equivalents � end of period

$

98,266

Ìý

Ìý

$

81,798

Ìý

Ìý

$

98,266

Ìý

Ìý

$

81,798

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Supplemental information of non-cash investing and financing information:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Right of use assets acquired in exchange for operating lease liabilities

$

�

Ìý

Ìý

$

1,194

Ìý

Ìý

$

�

Ìý

Ìý

$

1,958

Ìý

Property and equipment acquisitions through finance leases

$

�

Ìý

Ìý

$

333

Ìý

Ìý

$

�

Ìý

Ìý

$

6,862

Ìý

Purchase of property and equipment and capitalized software included in current liabilities

$

2,461

Ìý

Ìý

$

1,517

Ìý

Ìý

$

2,461

Ìý

Ìý

$

1,517

Ìý

Capitalized stock-based compensation

$

320

Ìý

Ìý

$

315

Ìý

Ìý

$

652

Ìý

Ìý

$

663

Ìý

Issuance of stock to settle liabilities for stock-based compensation

$

1,346

Ìý

Ìý

$

1,649

Ìý

Ìý

$

7,854

Ìý

Ìý

$

7,826

Ìý

Cash paid for:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Interest

$

330

Ìý

Ìý

$

381

Ìý

Ìý

$

654

Ìý

Ìý

$

864

Ìý

Income taxes

$

763

Ìý

Ìý

$

417

Ìý

Ìý

$

1,314

Ìý

Ìý

$

2,010

Ìý

Non-GAAP Financial Measures

This press release and statements made during the above-referenced webcast may include certain non-GAAP financial measures as defined by SEC rules.

Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity. We calculate Adjusted EBITDA as net income (loss) before interest income, net, income tax (benefit) expense, depreciation and amortization, and before stock-based compensation expense and other (income) expense, net.

We have provided below a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure. We have presented Adjusted EBITDA in this press release and our Quarterly Report on Form 10-Q to be filed after this press release because it is a key measure used by our management and board of directors to understand and evaluate our core operating performance and trends, to prepare and approve our annual budget, and to develop short and long-term operational plans. In particular, we believe that the exclusion of the amounts eliminated in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core business. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We have not reconciled our Adjusted EBITDA outlook to GAAP net income (loss) because we do not provide an outlook for GAAP net income (loss) due to the uncertainty and potential variability of other (income) expense, net and income tax (benefit) expense which are reconciling items between Adjusted EBITDA and GAAP net income (loss). Because we cannot reasonably predict such items, a reconciliation of the non-GAAP financial measure outlook to the corresponding GAAP measure is not available without unreasonable effort. We caution, however, that such items could have a significant impact on the calculation of GAAP net income (loss).

Our use of Adjusted EBITDA has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our financial results as reported under GAAP. Some of these limitations are as follows:

  • Although depreciation and amortization expense are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements;
  • Adjusted EBITDA does not reflect: (1) changes in, or cash requirements for, our working capital needs; (2) the potentially dilutive impact of non-cash stock-based compensation; (3) tax payments that may represent a reduction in cash available to us; or (4) interest income, net; and
  • Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled measures differently, which reduces its usefulness as a comparative measure.

Because of these and other limitations, you should consider Adjusted EBITDA along with other GAAP-based financial performance measures, including various cash flow metrics, net income (loss), and our GAAP financial results. The following table presents a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Adjusted EBITDA

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

(in thousands, unaudited)

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net income (loss)

$

654

Ìý

Ìý

$

(18,012

)

Ìý

$

(3,260

)

Ìý

$

(37,734

)

Interest income, net

Ìý

(608

)

Ìý

Ìý

(46

)

Ìý

Ìý

(378

)

Ìý

Ìý

(285

)

Income tax (benefit) expense

Ìý

(1,217

)

Ìý

Ìý

750

Ìý

Ìý

Ìý

(482

)

Ìý

Ìý

1,260

Ìý

Depreciation and amortization

Ìý

7,409

Ìý

Ìý

Ìý

7,303

Ìý

Ìý

Ìý

14,287

Ìý

Ìý

Ìý

13,976

Ìý

Stock-based compensation expense

Ìý

16,230

Ìý

Ìý

Ìý

16,448

Ìý

Ìý

Ìý

33,455

Ìý

Ìý

Ìý

33,288

Ìý

Other (income) expense, net

Ìý

(336

)

Ìý

Ìý

86

Ìý

Ìý

Ìý

(674

)

Ìý

Ìý

117

Ìý

Adjusted EBITDA

$

22,132

Ìý

Ìý

$

6,529

Ìý

Ìý

$

42,948

Ìý

Ìý

$

10,622

Ìý

We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment.

Additionally, free cash flow is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. We consider free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by our business that can be used for strategic opportunities, including investments, partnerships and acquisitions, and strengthening our financial position.

The following table presents a reconciliation of free cash flow from net cash provided by operating activities, the most directly comparable GAAP financial measure, for each of the periods indicated:

Phreesia, Inc.

Free cash flow

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

(in thousands, unaudited)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Net cash provided by operating activities

$

14,835

Ìý

Ìý

$

11,061

Ìý

Ìý

$

29,685

Ìý

Ìý

$

10,340

Ìý

Less:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Capitalized internal-use software

Ìý

(3,435

)

Ìý

Ìý

(2,976

)

Ìý

Ìý

(7,323

)

Ìý

Ìý

(7,546

)

Purchases of property and equipment

Ìý

(1,767

)

Ìý

Ìý

(4,427

)

Ìý

Ìý

(5,271

)

Ìý

Ìý

(5,303

)

Free cash flow

$

9,633

Ìý

Ìý

$

3,658

Ìý

Ìý

$

17,091

Ìý

Ìý

$

(2,509

)

Phreesia, Inc.

Reconciliation of GAAP and Adjusted Operating Expenses

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

(in thousands, unaudited)

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

GAAP operating expenses

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

General and administrative

$

19,042

Ìý

$

19,497

Ìý

$

35,450

Ìý

$

38,549

Sales and marketing

Ìý

25,396

Ìý

Ìý

30,184

Ìý

Ìý

51,439

Ìý

Ìý

62,195

Research and development

Ìý

29,274

Ìý

Ìý

29,542

Ìý

Ìý

61,103

Ìý

Ìý

58,423

Cost of revenue (excluding depreciation and amortization)

Ìý

17,398

Ìý

Ìý

16,143

Ìý

Ìý

34,035

Ìý

Ìý

31,866

Ìý

$

91,110

Ìý

$

95,366

Ìý

$

182,027

Ìý

$

191,033

Stock compensation included in GAAP operating expenses

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

General and administrative

$

6,362

Ìý

$

6,276

Ìý

$

12,935

Ìý

$

12,485

Sales and marketing

Ìý

4,745

Ìý

Ìý

5,303

Ìý

Ìý

9,919

Ìý

Ìý

11,069

Research and development

Ìý

4,204

Ìý

Ìý

3,629

Ìý

Ìý

8,597

Ìý

Ìý

7,256

Cost of revenue (excluding depreciation and amortization)

Ìý

919

Ìý

Ìý

1,240

Ìý

Ìý

2,004

Ìý

Ìý

2,478

Ìý

$

16,230

Ìý

$

16,448

Ìý

$

33,455

Ìý

$

33,288

Adjusted operating expenses

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

General and administrative

$

12,680

Ìý

$

13,221

Ìý

$

22,515

Ìý

$

26,064

Sales and marketing

Ìý

20,651

Ìý

Ìý

24,881

Ìý

Ìý

41,520

Ìý

Ìý

51,126

Research and development

Ìý

25,070

Ìý

Ìý

25,913

Ìý

Ìý

52,506

Ìý

Ìý

51,167

Cost of revenue (excluding depreciation and amortization)

Ìý

16,479

Ìý

Ìý

14,903

Ìý

Ìý

32,031

Ìý

Ìý

29,388

Ìý

$

74,880

Ìý

$

78,918

Ìý

$

148,572

Ìý

$

157,745

Phreesia, Inc.

Key Metrics

(Unaudited)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Key Metrics:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Average number of healthcare services clients ("AHSCs")

Ìý

4,467

Ìý

Ìý

4,169

Ìý

Ìý

4,439

Ìý

Ìý

4,117

Total revenue per AHSC

$

26,249

Ìý

$

24,494

Ìý

$

52,532

Ìý

$

49,388

The definitions of our key metrics are presented below.

  • AHSCs. We define AHSCs as the average number of clients that generate subscription and related services or payment processing fees revenue each month during the applicable period. In cases where we act as a subcontractor providing white-label services to our partner's clients, we treat the contractual relationship as a single healthcare services client. We believe growth in AHSCs is a key indicator of the performance of our business and depends, in part, on our ability to successfully develop and market our solutions to healthcare services organizations that are not yet clients. We believe growth in AHSCs provides useful information to investors as an important indicator of expected revenue growth. In addition, growth in AHSCs informs our management of the areas of our business that will require further investment to support expected future AHSC growth. For example, as AHSCs increase, we may need to add to our customer support team and invest to maintain effectiveness and performance of our solutions for our healthcare services clients and their patients.
  • Total revenue per AHSC. We define total revenue per AHSC as total revenue in a given period divided by the number of AHSCs during that same period. Our healthcare services clients directly generate subscription and related services and payment processing fees revenue. Additionally, our relationships with healthcare services clients who subscribe to our solutions give us the opportunity to engage with life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations who deliver direct communication to patients through our solutions. As a result, we believe that our ability to increase total revenue per AHSC provides useful information to investors as an indicator of the long-term value of our solutions.

Phreesia, Inc.

Additional Information

(Unaudited)

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Three months ended

July 31,

Ìý

Six months ended

July 31,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Patient payment volume (in millions)

$

1,250

Ìý

Ìý

$

1,093

Ìý

Ìý

$

2,564

Ìý

Ìý

$

2,259

Ìý

Payment facilitator volume percentage

Ìý

82

%

Ìý

Ìý

81

%

Ìý

Ìý

82

%

Ìý

81

%

  • Patient payment volume. We believe that patient payment volume is an indicator of both the underlying health of our healthcare services clientsâ€� businesses and the continuing shift of healthcare costs to patients. We measure patient payment volume as the total dollar volume of transactions between our healthcare services clients and their patients utilizing our payment platform, including via credit and debit cards that we process as a payment facilitator as well as cash and check payments and credit and debit transactions for which we act as a gateway to other payment processors.
  • Payment facilitator volume percentage. We define payment facilitator volume percentage as the volume of credit and debit card patient payments that we process as a payment facilitator as a percentage of total patient payment volume. Payment facilitator volume is a major driver of our payment processing fees revenue. Our payment facilitator volume percentage could decline slightly over time should we increase our penetration of enterprise customers that are less likely to use Phreesia as a payment facilitator.Ìý

1 Adjusted EBITDA is a non-GAAP measure. We calculate Adjusted EBITDA as net income (loss) before interest income, net, income tax (benefit) expense, depreciation and amortization, stock-based compensation expense and other (income) expense, net. See “Non-GAAP Financial Measures� for a reconciliation of Adjusted EBITDA to the closest GAAP measure.
2 Free cash flow is a non-GAAP measure. We calculate free cash flow as net cash provided by operating activities less capitalized internal-use software development costs and purchases of property and equipment. See “Non-GAAP Financial Measures� for a reconciliation of free cash flow to the closest GAAP measure.
3 GAAP is defined as generally accepted accounting principles in the United States.

Investor Relations Contact:

Balaji Gandhi

Phreesia, Inc.

[email protected]

(929) 506-4950

Media Contact:

Nicole Gist

Phreesia, Inc.

[email protected]

(407) 760-6274

Source: Phreesia, Inc.

Phreesia

NYSE:PHR

PHR Rankings

PHR Latest News

PHR Latest SEC Filings

PHR Stock Data

1.81B
56.77M
4.33%
100.74%
4.88%
Health Information Services
Services-business Services, Nec
United States
WILMINGTON